Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
J Clin Oncol
    August 2026
  1. LEUTHARDT EC, Chiang V, Hadjipanayis CG, Landazuri P, et al
    Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.
    J Clin Oncol. 2026 Aug 17:JCO2502604. doi: 10.1200/JCO-25-02604.
    >> Share

  2. KINSLOW CJ, Minniti G, Brown PD, Vogelbaum MA, et al
    Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.
    J Clin Oncol. 2026 Aug 12:JCO2501846. doi: 10.1200/JCO-25-01846.
    >> Share

    July 2026
  3. LIANG B, Weil M
    Corticosteroids in Glioblastoma Management: A Reconsideration of a 65-Year Practice.
    J Clin Oncol. 2026 Jul 22:JCO2600191. doi: 10.1200/JCO-26-00191.
    >> Share

  4. NABORS LB, Lobbous M, Han X, Fiveash J, et al
    Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma.
    J Clin Oncol. 2026 Jul 8:JCO2502463. doi: 10.1200/JCO-25-02463.
    >> Share

  5. MARCISCANO AE, Shih HA
    Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.
    J Clin Oncol. 2026 Jul 2:JCO2600771. doi: 10.1200/JCO-26-00771.
    >> Share

  6. BAUMERT BG, Hegi ME, van den Bent MJ, von Deimling A, et al
    Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).
    J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735.
    >> Share

    June 2026
  7. WILSON MR, Lewis KL, Kirkwood AA, Cwynarski K, et al
    High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
    J Clin Oncol. 2026 Jun 11:JCO2600947. doi: 10.1200/JCO-26-00947.
    >> Share

    May 2026
  8. KOTECHA R, Polley MY, Vogelbaum MA, Perry A, et al
    Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.
    J Clin Oncol. 2026 May 27:JCO2501441. doi: 10.1200/JCO-25-01441.
    >> Share

  9. RUDRA GUPTA T, Polley MC, Redd R, Lee EQ, et al
    Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
    J Clin Oncol. 2026 May 22:JCO2501586. doi: 10.1200/JCO-25-01586.
    >> Share

  10. LU S, Jia J, Ren K, Jia W, et al
    Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment.
    J Clin Oncol. 2026 May 14:JCO2502536. doi: 10.1200/JCO-25-02536.
    >> Share

  11. HANSFORD JR, Manoharan N, Khan S, Chon R, et al
    Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.
    J Clin Oncol. 2026 May 12:JCO2600461. doi: 10.1200/JCO-26-00461.
    >> Share

  12. BALLMAN KV
    Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma.
    J Clin Oncol. 2026 May 12:JCO2600444. doi: 10.1200/JCO-26-00444.
    >> Share

  13. WEN PY, Berry DA, Buxton MB, Colman H, et al
    Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
    J Clin Oncol. 2026 May 7:JCO2601027. doi: 10.1200/JCO-26-01027.
    >> Share

    April 2026
  14. WEN PY, Berry DA, Buxton MB, Colman H, et al
    Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
    J Clin Oncol. 2026 Apr 14:JCO2501137. doi: 10.1200/JCO-25-01137.
    >> Share

    March 2026
  15. COLMAN H, Lombardi G, Wong ET, Walbert T, et al
    STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
    J Clin Oncol. 2026;44:641-652.
    >> Share

  16. LI T, Zhou T, Wang B, Tao Z, et al
    Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
    J Clin Oncol. 2026 Mar 4:JCO2502021. doi: 10.1200/JCO-25-02021.
    >> Share

    January 2026
  17. RUSTHOVEN CG, Serizawa T, Yamamoto M
    Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials.
    J Clin Oncol. 2026 Jan 20:JCO2501794. doi: 10.1200/JCO-25-01794.
    >> Share

  18. NOGUCHI M, Nimura K, Koide Y
    Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501867. doi: 10.1200/JCO-25-01867.
    >> Share

  19. AKDOGAN O, Canaslan K, Hamitoglu B, Yazici O, et al
    Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501729. doi: 10.1200/JCO-25-01729.
    >> Share

  20. AIZER AA, Catalano PJ, Rahman R
    Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,"
    J Clin Oncol. 2026 Jan 20:JCO2502528. doi: 10.1200/JCO-25-02528.
    >> Share

    August 2025
  21. HUANG J
    Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib.
    J Clin Oncol. 2025 Aug 21:JCO2500967. doi: 10.1200/JCO-25-00967.
    >> Share

  22. PEROL M, Li W, Lai RK, Zhou C, et al
    Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
    J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
    >> Share

  23. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    >> Share

  24. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    >> Share

  25. LASSMAN AB, Polley MC, Iwamoto FM, Sloan AE, et al
    Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
    J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618.
    >> Share

    July 2025
  26. AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al
    Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
    J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.
    >> Share

    June 2025
  27. BLAKELEY J, Mohile NA, Messersmith H, Lassman AB, et al
    Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2025;43:2129-2133.
    >> Share

    April 2025
  28. SPERDUTO PW, Marqueen KE, Chang E, Li J, et al
    Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.
    J Clin Oncol. 2025 Apr 17:JCO2401351. doi: 10.1200/JCO-24-01351.
    >> Share

    March 2025
  29. WEISS SA, Djureinovic D, Wei W, Tran T, et al
    Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
    J Clin Oncol. 2025 Mar 6:JCO2402219. doi: 10.1200/JCO-24-02219.
    >> Share

    January 2025
  30. KACIMI SEO, Dehais C, Feuvret L, Chinot O, et al
    Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
    J Clin Oncol. 2025;43:329-338.
    >> Share

  31. HUANG RY, Youssef G, Nelson T, Wen PY, et al
    Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953.
    >> Share

    November 2024
  32. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    >> Share

  33. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    >> Share

    October 2024

  34. Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
    J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
    >> Share

    September 2024
  35. FORST DA, Podgurski AF, Strander SM, Whitman JD, et al
    NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors.
    J Clin Oncol. 2024 Sep 16:JCO2400065. doi: 10.1200/JCO.24.00065.
    >> Share

    August 2024
  36. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    >> Share

  37. JENG MY, Yu HA
    Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy.
    J Clin Oncol. 2024;42:2727-2730.
    >> Share

  38. LIN FY, Stuckert A, Tat C, White M, et al
    Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
    J Clin Oncol. 2024;42:2769-2779.
    >> Share

    July 2024
  39. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    >> Share

    June 2024
  40. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    >> Share

  41. KOTECHA R, Schiff D, Chakravarti A, Fleming JL, et al
    Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.
    J Clin Oncol. 2024 Jun 4:JCO2302195. doi: 10.1200/JCO.23.02195.
    >> Share

  42. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    >> Share

  43. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    >> Share

  44. MIKOLAJEWICZ N, Yee PP, Bhanja D, Trifoi M, et al
    Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application.
    J Clin Oncol. 2024;42:1961-1974.
    >> Share

    March 2024
  45. XIAO H, Vaidya R, Hershman DL, Unger JM, et al
    Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
    J Clin Oncol. 2024 Mar 27:JCO2301777. doi: 10.1200/JCO.23.01777.
    >> Share

    February 2024
  46. MARGOL AS, Molinaro AM, Onar-Thomas A, Resnick A, et al
    Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
    J Clin Oncol. 2024 Feb 23:JCO2301084. doi: 10.1200/JCO.23.01084.
    >> Share

  47. WU J, Heidelberg RE, Gajjar A
    Adolescents and Young Adults With Cancer: CNS Tumors.
    J Clin Oncol. 2024;42:686-695.
    >> Share

  48. ARRILLAGA-ROMANY I, Gardner SL, Odia Y, Aguilera D, et al
    ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
    J Clin Oncol. 2024 Feb 9:JCO2301134. doi: 10.1200/JCO.23.01134.
    >> Share

    December 2023
  49. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    >> Share

  50. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    >> Share

  51. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    >> Share

    November 2023
  52. HAAS-KOGAN DA, Aboian MS, Minturn JE, Leary SES, et al
    Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    J Clin Oncol. 2023 Nov 17:JCO2301838. doi: 10.1200/JCO.23.01838.
    >> Share

  53. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    >> Share

  54. FRIEDMAN HS, Prados MD, Wen PY, Mikkelsen T, et al
    Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4945-4952.
    >> Share

  55. MELLINGHOFF IK
    Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
    J Clin Oncol. 2023;41:4943-4944.
    >> Share

    October 2023
  56. LEWIS KL, Jakobsen LH, Villa D, Smedby KE, et al
    High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2023 Oct 5:JCO2300365. doi: 10.1200/JCO.23.00365.
    >> Share

    September 2023
  57. WEN PY, van den Bent M, Youssef G, Cloughesy TF, et al
    RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
    J Clin Oncol. 2023 Sep 29:JCO2301059. doi: 10.1200/JCO.23.01059.
    >> Share

  58. BANU MA, McKhann GM
    Maximizing Extent of Resection for Noneloquent Glioblastoma: Fluorescent Dye or Intraoperative Magnetic Resonance Imaging?
    J Clin Oncol. 2023 Sep 18:JCO2300963. doi: 10.1200/JCO.23.00963.
    >> Share

  59. RAHMAN R, Trippa L, Lee EQ, Arrillaga-Romany I, et al
    Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
    J Clin Oncol. 2023 Sep 18:JCO2300493. doi: 10.1200/JCO.23.00493.
    >> Share

    August 2023
  60. HARGRAVE DR, Terashima K, Hara J, Kordes UR, et al
    Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol. 2023 Aug 29:JCO2300558. doi: 10.1200/JCO.23.00558.
    >> Share

  61. LU BY, Goldberg SB
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Aug 21:JCO2301323. doi: 10.1200/JCO.23.01323.
    >> Share

  62. NADAL E, Rodriguez-Abreu D, Simo M, Massuti B, et al
    Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
    J Clin Oncol. 2023 Aug 21:JCO2202561. doi: 10.1200/JCO.22.02561.
    >> Share

    June 2023
  63. RODER C, Stummer W, Coburger J, Scherer M, et al
    Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.
    J Clin Oncol. 2023 Jun 19:JCO2201862. doi: 10.1200/JCO.22.01862.
    >> Share

  64. NEGRAO MV, Spira AI, Heist RS, Janne PA, et al
    Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
    J Clin Oncol. 2023 Jun 16:JCO2300046. doi: 10.1200/JCO.23.00046.
    >> Share

  65. DUMMER R, Corrie P, Gutzmer R, Meniawy TM, et al
    First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    J Clin Oncol. 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
    >> Share

    May 2023
  66. WARREN KE, Vezina G, Krailo M, Springer L, et al
    Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.
    J Clin Oncol. 2023 May 1:JCO2201777. doi: 10.1200/JCO.22.01777.
    >> Share

    April 2023
  67. HSU TW, Liang CS, Tsai SJ, Bai YM, et al
    Risk of Major Psychiatric Disorders Among Children and Adolescents Surviving Malignancies: A Nationwide Longitudinal Study.
    J Clin Oncol. 2023;41:2054-2066.
    >> Share

  68. YOUSSEF G, Rahman R, Bay C, Wang W, et al
    Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
    J Clin Oncol. 2023 Apr 7:JCO2201579. doi: 10.1200/JCO.22.01579.
    >> Share

    March 2023
  69. MUTTER JA, Alig SK, Esfahani MS, Lauer EM, et al
    Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    J Clin Oncol. 2023;41:1684-1694.
    >> Share

    February 2023
  70. DIEZ VALLE R
    Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.
    J Clin Oncol. 2023 Feb 28:JCO2202428. doi: 10.1200/JCO.22.02428.
    >> Share

    January 2023
  71. GROMMES C
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016